Method for determining the risk of developing liver cancer, a kit for determining the risk of developing liver cancer, and a pharmaceutical composition
PROBLEM TO BE SOLVED: To provide a method for determining a risk of developing liver cancer and a kit for determining the risk of developing liver cancer, which can determine the risk of developing liver cancer regardless of the hepatitis virus. A method for determining a risk of developing liver cancer, which comprises a step of measuring the content of a gelE gene or a gene product thereof in a target fecal sample. A kit for determining the risk of developing liver cancer, which comprises a reagent for measuring the content of the gelE gene in the target fecal sample. Further, a pharmaceutical composition for reducing the risk of developing liver cancer, which is administered to a subject determined to have a high risk of developing liver cancer by the method for determining the risk of developing liver cancer, and is a large intestine of the subject. A pharmaceutical composition comprising an agent that reduces the number of bacteria having the gelE gene within. [Selection diagram] None【課題】肝炎ウイルスとは無関係に、肝臓がん発症リスクを判定可能な、肝がん発症リスクの判定方法、及び肝がん発症リスクの判定キットを提供する。【解決手段】対象の糞便試料において、ｇｅｌＥ遺伝子又はその遺伝子産物の含有量を測定する工程を含む、肝臓がん発症リスクの判定方法。また、対象の糞便試料中のｇｅｌＥ遺伝子の含有量を測定するための試薬を含む、肝臓がん発症リスクの判定キット。また、前記肝臓がん発症リスクの判定方法により肝臓がん発症リスクが高いと判定された対象に投与される、肝臓がん発症リスクを低減するための医薬組成物であって、前記対象の大腸内のｇｅｌＥ遺伝子を有する細菌の数を減少させる薬剤を含む、医薬組成物。【選択図】なし
